PMID- 24489939
OWN - NLM
STAT- MEDLINE
DCOM- 20141006
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 1
DP  - 2014
TI  - Association of matrix metalloproteinase-3 -1171(5A>6A) polymorphism with cancer 
      risk: a meta-analysis of 41 studies.
PG  - e87562
LID - 10.1371/journal.pone.0087562 [doi]
LID - e87562
AB  - BACKGROUND AND OBJECTIVE: Evidence has shown that matrix metalloproteinases-3 
      (MMP3) is important for cancer progression. Recent studies about the association 
      between the -1171(5A>6A) polymorphism in MMP3 promoter region and cancer risk 
      have yielded conflicting results. METHODOLOGY/PRINCIPAL FINDINGS: We performed a 
      meta-analysis of 41 studies including 11112 cases and 11091 controls to determine 
      whether the -1171(5A>6A) polymorphism of MMP3 was associated with cancer risk. We 
      assessed the strength of association and performed sub-group analyses by cancer 
      types, ethnicity, smoking status, genotyping method, source of controls and 
      sample size. The pooled results revealed that no significant association of the 
      -1171(5A>6A) polymorphism with overall cancer risk in any of four models. Further 
      sub-group analysis revealed that individuals with the 6A allele had lower risk of 
      gastrointestinal cancer in two models: heterozygote comparison (6A/5A vs. 5A/5A: 
      OR=0.74, 95%CI: 0.60-0.91; I(2)=1.9%), and dominant model (6A/6A+6A/5A vs. 5A/5A: 
      OR=0.77, 95%CI: 0.64-0.94; I(2)=29.0%). Additionally, the associations were 
      significant in Asian populations for three models: homozygote comparison (6A/6A 
      vs. 5A/5A, OR=0.68, 95%CI: 0.52-0.90; I(2)=26.7%), heterozygote comparison (6A/5A 
      vs. 5A/5A: OR=0.75, 95%CI: 0.58-0.98; I(2)=0.0%), and dominant model (6A/6A+6A/5A 
      vs. 5A/5A: OR=0.69, 95%CI: 0.54-0.88; I(2)=0.5%). It was noteworthy that we had a 
      contrary finding in non-smokers: the variant 6A/6A homozygote might statistically 
      increase cancer risk compared with 6A/5A+5A/5A genotype (OR=1.92, 95%CI: 
      1.25-2.96; I(2)=72.7%). CONCLUSION: This meta-analysis suggests that the 
      -1171(5A>6A) polymorphism in MMP3 promoter region is not associated with overall 
      cancer risk, but it may contribute to decreased cancer risk in Asian population 
      when compared with Caucasian population and significantly reduce the risk of 
      gastrointestinal cancer.
FAU - Yang, Xin
AU  - Yang X
AD  - The First Clinical College of Nanjing Medical University, Nanjing, China ; 
      Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer 
      Hospital, Cancer Institute of Jiangsu Province, Nanjing, China ; Jiangsu Key 
      Laboratory of Molecular and Translational Cancer Research, Nanjing, China.
FAU - Hu, Jing-Wen
AU  - Hu JW
AD  - Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer 
      Hospital, Cancer Institute of Jiangsu Province, Nanjing, China ; Jiangsu Key 
      Laboratory of Molecular and Translational Cancer Research, Nanjing, China.
FAU - Qiu, Man-Tang
AU  - Qiu MT
AD  - Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer 
      Hospital, Cancer Institute of Jiangsu Province, Nanjing, China ; Jiangsu Key 
      Laboratory of Molecular and Translational Cancer Research, Nanjing, China.
FAU - Li, Ming
AU  - Li M
AD  - Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer 
      Hospital, Cancer Institute of Jiangsu Province, Nanjing, China ; Jiangsu Key 
      Laboratory of Molecular and Translational Cancer Research, Nanjing, China.
FAU - Yin, Rong
AU  - Yin R
AD  - Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer 
      Hospital, Cancer Institute of Jiangsu Province, Nanjing, China ; Jiangsu Key 
      Laboratory of Molecular and Translational Cancer Research, Nanjing, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, 
      China ; Department of Scientific Research, Nanjing Medical University Affiliated 
      Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, China.
FAU - Xu, Lin
AU  - Xu L
AD  - Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer 
      Hospital, Cancer Institute of Jiangsu Province, Nanjing, China ; Jiangsu Key 
      Laboratory of Molecular and Translational Cancer Research, Nanjing, China.
FAU - Zhang, Qin
AU  - Zhang Q
AD  - Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer 
      Hospital, Cancer Institute of Jiangsu Province, Nanjing, China ; Jiangsu Key 
      Laboratory of Molecular and Translational Cancer Research, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140129
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Case-Control Studies
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - INDEL Mutation
MH  - Matrix Metalloproteinase 3/*genetics
MH  - Neoplasms/*genetics
MH  - Polymorphism, Genetic
MH  - Risk
PMC - PMC3906197
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/02/04 06:00
MHDA- 2014/10/07 06:00
PMCR- 2014/01/29
CRDT- 2014/02/04 06:00
PHST- 2013/10/08 00:00 [received]
PHST- 2013/12/21 00:00 [accepted]
PHST- 2014/02/04 06:00 [entrez]
PHST- 2014/02/04 06:00 [pubmed]
PHST- 2014/10/07 06:00 [medline]
PHST- 2014/01/29 00:00 [pmc-release]
AID - PONE-D-13-41143 [pii]
AID - 10.1371/journal.pone.0087562 [doi]
PST - epublish
SO  - PLoS One. 2014 Jan 29;9(1):e87562. doi: 10.1371/journal.pone.0087562. eCollection 
      2014.